Recombinant Human DOCK4, N-His

Description of Recombinant Human DOCK4, N-His

Title: Introduction to Recombinant Human DOCK4

Recombinant Human DOCK4 is a protein that plays a crucial role in cell signaling and has been widely studied for its potential therapeutic applications. This protein is encoded by the DOCK4 gene and is a member of the DOCK family of proteins. In this article, we will explore the structure, activity, and potential applications of Recombinant Human DOCK4.

Title: Structure of Recombinant Human DOCK4

Recombinant Human DOCK4 is a large protein consisting of 2,487 amino acids with a molecular weight of approximately 280 kDa. It contains several conserved domains, including the DHR-1 and DHR-2 domains, which are responsible for its GTPase activity. The DHR-1 domain is involved in guanine nucleotide exchange, while the DHR-2 domain is responsible for binding to phospholipids.

Title: Activity of Recombinant Human DOCK4

Recombinant Human DOCK4 is a guanine nucleotide exchange factor (GEF) that activates the small GTPase protein Rac1. GEFs are important regulators of cell signaling pathways and play a crucial role in cell proliferation, migration, and invasion. DOCK4 specifically activates Rac1, which in turn activates downstream signaling pathways involved in cell adhesion, cytoskeletal reorganization, and gene expression.

Title: Role of Recombinant Human DOCK4 in Cancer

The activity of Recombinant Human DOCK4 is closely linked to cancer progression. Studies have shown that DOCK4 is overexpressed in various types of cancer, including breast, lung, and colon cancer. Overexpression of DOCK4 has been associated with increased cell proliferation, migration, and invasion, making it a potential therapeutic target for cancer treatment.

Title: Potential Applications of Recombinant Human DOCK4

Recombinant Human DOCK4 has been extensively studied for its potential therapeutic applications. One of the most promising applications is in cancer treatment. Inhibiting DOCK4 activity could potentially slow down cancer progression and inhibit metastasis. Additionally, DOCK4 has also been implicated in other diseases, such as cardiovascular diseases and neurological disorders, making it a potential target for therapeutic intervention in these conditions.

Title: Production of Recombinant Human DOCK4

Recombinant Human DOCK4 can be produced in various expression systems, including bacterial, yeast, and mammalian cells. The most commonly used system is the Chinese hamster ovary (CHO) cell line, which allows for proper post-translational modifications and yields a highly pure and active protein. The protein is then purified using chromatography techniques, ensuring its quality and activity for further studies and applications.

Title: Use of Recombinant Human DOCK4 as an Antigen

Recombinant Human DOCK4 has also been used as an antigen in immunological studies. Antibodies against DOCK4 have been developed and used to detect its expression in different tissues and cell types. Furthermore, DOCK4 has been identified as a potential antigen for cancer immunotherapy, where it could be targeted by specific antibodies to inhibit its activity and slow down cancer progression.

In conclusion, Recombinant Human DOCK4 is a crucial protein involved in cell signaling and has been extensively studied for its potential therapeutic applications. Its structure, activity, and potential applications make it a promising target for cancer treatment and other diseases. With further research and development, Recombinant Human DOCK4 could potentially be used as a diagnostic marker and a therapeutic agent in various diseases.